Index Options
CME Group
Nasdaq
Cboe
TradingView
Wall Street JournalNews
PDSB
1.230
-2.38%
-0.030
PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Benzinga · 1d ago
PDS Biotech gets IND application clearance for colorectal cancer treatment
Seeking Alpha · 1d ago
PDS BIOTECH ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR COMBINATION OF VERSAMUNE® MUC1 AND PDS01ADC TO TREAT METASTATIC COLORECTAL CANCER
Reuters · 1d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 4d ago
Weekly Report: what happened at PDSB last week (0303-0307)?
Weekly Report · 4d ago
PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 03/07 17:47
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Benzinga · 03/07 17:36
PDS Biotechnology’s Promising Phase 3 Trial and Strong Clinical Foundation Justify Buy Rating
TipRanks · 03/07 15:45
PDS Biotechnology initiates VERSATILE-003 Phase 3 trial of Versamune HPV
TipRanks · 03/07 13:51
PDS BIOTECH INITIATES VERSATILE-003 PHASE 3 CLINICAL TRIAL EVALUATING VERSAMUNE® HPV IN HPV16-POSITIVE HEAD AND NECK CANCER
Reuters · 03/07 13:45
Insider Buying Surge at PDS Biotechnology!
TipRanks · 03/04 02:14
Weekly Report: what happened at PDSB last week (0224-0228)?
Weekly Report · 03/03 10:13
PDS Biotechnology prices 7.33M shares at $1.50 in registered direct offering
TipRanks · 02/27 13:31
PDS BIOTECH ANNOUNCES UP TO $22 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 02/27 13:00
PDS announces data on survival, clinical responses in HPV-associated cancers
TipRanks · 02/26 13:27
PDS Biotech Announces Clinical Data Demonstrating Compelling Survival And Clinical Responses In Recurrent/Metastatic HPV-Associated Cancers Published In JAMA Oncology; Significant Tumor Shrinkage With Confirmed Objective Response Rate Of 75% In HPV16-Positive Immune Checkpoint Inhibitor Naïve Patients; Historically Published Result Is 11-24%
Benzinga · 02/26 13:05
PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 02/24 16:30
Promising Efficacy of PDS Biotechnology’s Versamune Platform in Cervical Cancer Treatment Drives Buy Rating
TipRanks · 02/24 16:25
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Benzinga · 02/24 16:20
More
Webull provides a variety of real-time PDSB stock news. You can receive the latest news about Pds Biotechnology Corporation through multiple platforms. This information may help you make smarter investment decisions.
About PDSB
MorePDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.